Trial Profile

Effect of Burosumab and 1-25 (OH) Vitamin D on Human Osteoclasts From Patients With Hypophosphatemic Rickets (HR)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Burosumab (Primary) ; Calcitriol (Primary)
Indications X-linked dominant hypophosphataemic rickets
Focus Therapeutic Use
Acronyms HYPO-CLASTE

Most Recent Events

05 Oct 2022 Status changed from recruiting to completed.
16 Apr 2021 Protocol amended to include Controls group patients. Number of arms increased from 1 to 2 as well as planned patient number increased from 15 to 40.
16 Apr 2021 Planned number of patients changed from 15 to 40.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com